Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer

Cancer

Volumn 118, Issue 18, 2012, Pages 4486-4494

  Camidge, D Ross ^a   Theodoro, Mariana ^a   Maxson, Delee A ^a   Skokan, Margaret ^a   O'Brien, Tara ^a   Lu, Xian ^b   Doebele, Robert C ^a   Barõn, Anna E ^b   Varella Garcia, Marileila ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Global Health and Health Disparities   (United States)

Author keywords

anaplastic lymphoma kinase; copy number; crizotinib; fluorescence in situ hybridization

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ANAPLASTIC LYMPHOMA KINASE GENE; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; COPY NUMBER VARIATION; DIPLOIDY; DRUG EFFICACY; ENZYME INHIBITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA COPY NUMBER VARIATIONS; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84864432794     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27411     Document Type: Review

References (13)

1. Solomon B, Varella-Garcia M, Camidge DR,. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009; 4: 1450-1454.
2. Mano H,. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. Cancer Sci. 2008; 99: 2349-2355.
3. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-566.
4. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007; 131: 1190-1203.
5. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res. 2009; 15: 3143-3149.
6. Camidge DR, Hirsch FR, Varella-Garcia M, Franklin WA,. Finding ALK positive lung cancer: what are we really looking for? J Thorac Oncol. 2011; 6: 411-413.
7. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693-1703.
8. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer. In: Proceedings of the 2011 ASCO Annual Meeting; June 4-8, 2011; Chicago, IL. Abstract 2501.
9. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res. 2010; 16: 5581-5590.
10. Salido M, Pijuan L, Martínez-Avilés L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol. 2011; 6: 21-27.
11. Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009; 174: 661-670.
12. Palmer RH, Vernersson E, Grabbe C, Hallberg B,. Anaplastic lymphoma kinase: signalling in development and disease. Biochem J. 2009; 420: 345-361.
13. Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C,. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer. 2003; 3: 695-701.